NEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. About Betagan (Levobunolol) without Rx (Tyme, Inc.) (OTC QB:TYMI), a research and development company focused on developing first-in-class oncology drug candidates, has appointed W. Vasotec (Enalapril) Kevin Kelly, DO to serve on its Scientific and Medical Advisory Board. Lamictal (Lamotrigine) with no Rx Dr. Buy Furosemide Kelly, an internationally respected expert in the field of urological malignancies, is Director of the solid tumor division in the Department of Medical Oncology and Associate Director of Translational Research at the Thomas Jefferson University Hospital Kimmel Cancer Center in Philadelphia. “I am honored to welcome Dr. Buy Furoxone (Furazolidone) with free Rx Kelly to our Scientific and Medical Advisory Board,” said Steve Hoffman, President and Chief Executive Officer of Tyme, Inc. Buy Diuretics online “Our goal was to assemble a world class team of thought leaders, and Dr. http://cholesterolreviews.wordpress.com Kelly’s tremendous medical expertise and well-deserved accolades make him an important addition. I am very excited about the group of advisors we have brought together and optimistic that their guidance will help us to reach our oncology product development goals.” Prior to joining the Jefferson faculty, Dr. Kelly directed the solid tumor clinical investigative program at Yale University School of Medicine, where he also co-directed the prostate and urological oncology programs. He spent the previous 15 years on the faculty at Memorial-Sloan Kettering Cancer Center. Dr. Kelly earned his undergraduate degree from Emory University and received his DO from Philadelphia College of Osteopathic Medicine. He did his residency at Albert Einstein Medical Center and completed his fellowship training in medical oncology at Memorial-Sloan Kettering Cancer Center. Dr. Kelly’s main clinical research focus has been in the area of genitourinary cancers, and he is a leading expert in the development of novel treatment strategies and targeted agents for prostate cancer and other urologic cancers. His research has focused on developing novel designs and biomarkers for prostate cancer and his research linking elevated prostate-specific antigen levels to prostate cancer treatment outcomes remains a foundation for drug development in patients with advanced prostate cancer today. More recently, he has been instrumental in developing multiple compounds such as microtubule disrupting agents, histone deacetylase (HDAC) inhibitors and anti-angiogenesis therapies for urologic cancers. He has successfully developed several new drugs from bench through clinical trial and approval. He continues to work closely with scientists, as well as with investigators to develop these agents. Dr. Kelly is board certified in Internal Medicine and Medical Oncology. He serves on numerous editorial boards such as Journal of Clinical Oncology, Clinical Prostate Cancer and Nature Clinical Practice Oncology. About Tyme, Inc. Tyme, Inc. is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme, Inc. is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic characteristics of cancer cells as well as activating the endogenous immune response against tumors. Tyme, Inc. s approach is hypothesized to permit selective elimination of cancer cells, while simultaneously improving patients well-being, particularly with respect to pain severity and functional independence. Tyme, Inc. is currently developing for use in humans SM-88, a proprietary compound, which the company believes to be a first-in-class drug that harnesses the body’s own immune defenses to fight tumor cells. SM-88 is a novel combination drug that synergistically targets the unique metabolic features of cancer cells, thus providing a selective method of altering the susceptibility of cancer cells to oxidative stress. Tyme, Inc. has completed a proof-of-concept clinical study for SM-88 in late-stage cancer patients with relapsed or highly refractory disease. For more information, visit our website: .tymetechnologiesinc.com. Safe Harbor Statement This press release contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned "Risk Factors" of Tyme, Inc. s Current Report on Form 8-K/A filed with the U.S. Securities and Exchange Commission on April 16, 2015 (available at .sec.gov). Readers can identify forward-looking statements by terms such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements, and forward-looking statements within this press release include statements regarding our drug development strategies, clinical trials and plans for submitting an IND with the FDA. Forward-looking statements reflect the Company’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, readers should not place undue reliance on these forward-looking statements.